To The Editor: In his Commentary on health care in the age of genetic medicine, Dr Evans1 highlights the advent of individualized medicine as a “threshold that is so monumental it mandates changes in the structure of health care delivery” and notes that “[d]riven by advances in genomics, emerging insight into each individual's unique susceptibility to disease promises to transform patient care.”1 He draws attention to technology that is also relevant to the Commentary by Drs Hudis and Modi,2 in which they note that postoperative adjuvant chemotherapy initially “required a shift in thinking . . . because it included the use of potentially toxic drugs in patients, some of whom were presumably already cured of malignancy.”2
Anesi GL. Genetically Guided Choices for Chemotherapy. JAMA. 2008;299(13):1543–1544. doi:10.1001/jama.299.13.1543-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: